Schnieders Capital Management LLC Cuts Holdings in Johnson & Johnson (NYSE:JNJ)

Schnieders Capital Management LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 10.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 78,489 shares of the company's stock after selling 9,576 shares during the period. Johnson & Johnson accounts for approximately 2.7% of Schnieders Capital Management LLC's portfolio, making the stock its 8th largest position. Schnieders Capital Management LLC's holdings in Johnson & Johnson were worth $12,302,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of JNJ. Pathway Financial Advisors LLC increased its stake in shares of Johnson & Johnson by 4.3% during the fourth quarter. Pathway Financial Advisors LLC now owns 5,438 shares of the company's stock valued at $852,000 after purchasing an additional 226 shares in the last quarter. Daiwa Securities Group Inc. grew its holdings in shares of Johnson & Johnson by 5.5% during the fourth quarter. Daiwa Securities Group Inc. now owns 297,850 shares of the company's stock valued at $46,685,000 after buying an additional 15,490 shares during the last quarter. DORCHESTER WEALTH MANAGEMENT Co grew its holdings in shares of Johnson & Johnson by 0.6% during the third quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 75,495 shares of the company's stock valued at $11,758,000 after buying an additional 414 shares during the last quarter. OneAscent Financial Services LLC grew its holdings in shares of Johnson & Johnson by 82.8% during the fourth quarter. OneAscent Financial Services LLC now owns 9,838 shares of the company's stock valued at $1,542,000 after buying an additional 4,457 shares during the last quarter. Finally, TrueMark Investments LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $1,458,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 0.5 %

NYSE JNJ traded up $0.70 on Monday, hitting $146.84. 6,461,311 shares of the stock were exchanged, compared to its average volume of 7,363,774. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97. The company has a market cap of $353.85 billion, a PE ratio of 9.15, a PEG ratio of 2.41 and a beta of 0.53. The company has a 50-day moving average price of $155.07 and a 200-day moving average price of $155.23.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.64 by $0.07. The firm had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.43%. Johnson & Johnson's revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.68 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be issued a dividend of $1.24 per share. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a dividend yield of 3.38%. The ex-dividend date is Monday, May 20th. Johnson & Johnson's dividend payout ratio is presently 29.68%.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 59,397 shares of the firm's stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the transaction, the executive vice president now owns 141,416 shares in the company, valued at $22,099,078.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares of the company's stock, valued at $22,099,078.32. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now directly owns 4,099,575 shares of the company's stock, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on JNJ shares. Raymond James increased their price target on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an "outperform" rating in a report on Wednesday, January 3rd. Royal Bank of Canada reduced their price target on shares of Johnson & Johnson from $181.00 to $175.00 and set an "outperform" rating on the stock in a report on Wednesday, April 17th. Bank of America reduced their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, April 17th. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, February 6th. Finally, Morgan Stanley dropped their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an "equal weight" rating for the company in a research note on Wednesday, April 17th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and an average target price of $175.86.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.